PriceTargets.com logo

Reneo Pharmaceuticals - RPHM Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.50
  • Forecasted Upside: -17.58%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.82 As of 10/4/2024 05:00 PM ET
▲ +0.09 (5.20%)
Get New Reneo Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RPHM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RPHM

Analyst Price Target is $1.50
▼ -17.58% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Reneo Pharmaceuticals in the last 3 months. The average price target is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a -17.58% upside from the last price of $1.82.

This chart shows the closing price for RPHM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Reneo Pharmaceuticals. This rating changed within the last month from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/14/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$1.50
12/15/2023Leerink PartnersReiterated RatingOutperform ➝ Market Perform
12/15/2023Jefferies Financial GroupReiterated RatingBuy ➝ Hold
12/15/2023HC WainwrightDowngradeBuy ➝ Neutral
12/14/2023LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
12/14/2023Bank of AmericaDowngradeBuy ➝ Underperform
12/14/2023William BlairDowngradeOutperform ➝ Market Perform
12/14/2023Piper SandlerDowngradeOverweight ➝ Neutral$25.00 ➝ $4.00
12/14/2023Robert W. BairdDowngradeOutperform ➝ Neutral$28.00 ➝ $3.00
11/15/2023William BlairInitiated CoverageOutperform$35.55
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$30.00
10/12/2023HC WainwrightReiterated RatingBuy ➝ Buy$30.00
9/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$30.00
8/28/2023HC WainwrightInitiated CoverageBuy$30.00
7/3/2023Bank of AmericaInitiated CoverageBuy
9/19/2022HC WainwrightReiterated RatingBuy$31.00
7/26/2022Piper SandlerBoost TargetOutperform$18.00 ➝ $25.00
5/17/2022Piper SandlerLower TargetOverweight$45.00 ➝ $18.00
5/10/2022Leerink PartnersReiterated RatingOutperform
3/24/2022Leerink PartnersLower TargetOutperform$25.00 ➝ $15.00
1/26/2022Robert W. BairdInitiated CoverageOutperform$28.00
12/21/2021HC WainwrightInitiated CoverageBuy$28.00
11/22/2021LADENBURG THALM/SH SHInitiated CoverageBuy$45.00
5/23/2021Leerink PartnersReiterated RatingBuy$25.00
5/4/2021Leerink PartnersInitiated CoverageOutperform$25.00
5/4/2021Jefferies Financial GroupInitiated CoverageBuy$24.00
5/4/2021Piper SandlerInitiated CoverageOverweight$45.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Reneo Pharmaceuticals logo
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $1.82
Low: $1.68
High: $1.90

50 Day Range

MA: $1.64
Low: $1.31
High: $1.82

52 Week Range

Now: $1.82
Low: $0.98
High: $9.21

Volume

437,500 shs

Average Volume

250,384 shs

Market Capitalization

$60.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Reneo Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Reneo Pharmaceuticals in the last twelve months: HC Wainwright.
View the latest analyst ratings for RPHM.

What is the current price target for Reneo Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Reneo Pharmaceuticals in the last year. Their average twelve-month price target is $1.50, suggesting a possible downside of 17.6%. HC Wainwright has the highest price target set, predicting RPHM will reach $1.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.50 for Reneo Pharmaceuticals in the next year.
View the latest price targets for RPHM.

What is the current consensus analyst rating for Reneo Pharmaceuticals?

Reneo Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RPHM, but not buy more shares or sell existing shares.
View the latest ratings for RPHM.

What other companies compete with Reneo Pharmaceuticals?

Other companies that are similar to Reneo Pharmaceuticals include Fulcrum Therapeutics, Aurora Cannabis, Lexeo Therapeutics, Tenaya Therapeutics and Fate Therapeutics. Learn More about companies similar to Reneo Pharmaceuticals.

How do I contact Reneo Pharmaceuticals' investor relations team?

The company's listed phone number is 858-283-0280 and its investor relations email address is [email protected]. The official website for Reneo Pharmaceuticals is reneopharma.com. Learn More about contacing Reneo Pharmaceuticals investor relations.